Format
Sort by

Send to:

Choose Destination

Search results

Items: 3

1.

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.

Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators.

N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839.

2.

Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease.

Blennow K, Zetterberg H, Rinne JO, Salloway S, Wei J, Black R, Grundman M, Liu E; AAB-001 201/202 Investigators.

Arch Neurol. 2012 Aug;69(8):1002-10.

PMID:
22473769
3.

Isolated photosystem I reaction centers on a functionalized gated high electron mobility transistor.

Eliza SA, Lee I, Tulip FS, Mostafa S, Greenbaum E, Ericson MN, Islam SK.

IEEE Trans Nanobioscience. 2011 Sep;10(3):201-8. doi: 10.1109/TNB.2011.2164809. Epub 2011 Sep 15.

PMID:
21926029
Format
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk